Physician profile
Karnail Singh
NPI 1871593202
$1,676.15
in general payments reported to CMS, 2019-2025
18 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $122 · 2021: $304 · 2022: $260 · 2023: $166 · 2024: $153 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.53 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $405.67 | 2021-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $306.16 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $229.02 | 2019-2022 | |
| Esperion Therapeutics, INC. | $126.47 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $103.94 | 2019-2025 | Breztri, Airsupra |
| Arbor Pharmaceuticals, INC. | $71.34 | 2019 | |
| Medtronic USA, INC. | $70.82 | 2019 | |
| Lilly USA, LLC | $67.33 | 2019-2020 | |
| Bausch Health US, LLC | $56.40 | 2021 | |
| Shire North American Group INC | $54.18 | 2019 | |
| Abbott Laboratories | $43.21 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $31.72 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $21.58 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.45 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.41 | 2025 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $18.45 | 2022 | |
| Melinta Therapeutics, LLC | $18.18 | 2019 | |
| Glaxosmithkline, LLC. | $12.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karnail Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.